Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus

Conclusions/interpretationMEDI4166 was associated with an acceptable tolerability profile and significantly decreased LDL-cholesterol levels in a dose-dependent manner in overweight or obese patients with type 2 diabetes. However, there were no significant reductions in postprandial glucose levels at any dose of MEDI4166.Trial registrationClinicalTrials.gov NCT02524782FundingThis study was funded by MedImmune LLC, Gaithersburg, MD, USA.

Source: Diabetologia - February 13, 2019 Category: Endocrinology Source Type: research